Insight Molecular Diagnostics amends Chronix merger royalty terms again
The September 15, 2026 amendment narrows the equity holders' royalty to CNI Monitor sales specifically and adds a final payment tied to any future sale of the test.
SEC filing
Latest
2 stories
Monday, September 21
Monday, August 10
iMDx says FDA sought more data on GraftAssureDx, gives itself 180 days to answer
The company disclosed an FDA Additional Information Request tied to its transplant test kit and reported a Q2 2026 net loss of $11.3 million.
SEC filing